CALGARY, Canada, December 21 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) has completed patient enrolment in its Phase Ia/Ib U.K. clinical trial investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN(R) at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The treatment appears to have been well tolerated by the patients and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers.

ZUG, Switzerland, December 21 /PRNewswire/ -- AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business.

DÜSSELDORF, Germany, December 21 /PRNewswire/ --

- Consistent Continuation of Globalisation Path and Extension of Product Offerings

LONDON, December 21 /PRNewswire/ --

- Prenatal Omega 3 Supplementation has Long-Term Health Benefits for Unborn Babies

A new longitudinal study has shown that the benefits of prenatal omega 3 supplementation extend to the child's motor function in later life(1). The study, conducted in the Netherlands over 7 years, followed 300 children and related their motor abilities back to umbilical blood samples, which showed the levels of omega 3 essential fatty acid, Docosahexaenoic Acid (DHA) at the time of birth.

LONDON, December 21 /PRNewswire/ --

- Virgin Active Offers Healthy Advice on Joining Gyms in 2008

At a time when it is feared that mortgage debts are rising as quickly as obesity levels, Virgin Active has come up with suggestions to help people make an informed investment when joining a health club. The ideas that follow will enable individuals to remain financially sensible whilst trying to combat a tightening pinch around their waist lines as well as their wallets.

Top tips:

- Make sure that a sales representative fully explains the terms and conditions to you before you sign. If you don't have time, take the contract home and go through it at your leisure so you know what you are committing to.

MELBOURNE, Australia, December 21 /PRNewswire/ --

Starpharma Holdings Limited (ASX:SPL, OTC: SPHRY), developer of VivaGel(R) vaginal microbicide today welcomed a decision by the US FDA this week requiring makers of products containing nonoxynol 9 (N9) to carry a warning that the products do not protect against sexually transmitted diseases, including HIV/AIDS and that the use of N-9 products is associated with an increased risk of HIV.

Starpharma's VivaGel(R) is a vaginal gel, being developed to protect women from HIV and HSV-2 (genital herpes) during sex. VivaGel(R) does not use N9. VivaGel(R) is currently in mid-stage clinical trials in the US and Kenya to add to its portfolio of safety data before embarking on population-based efficacy testing.